Circulating cell-free DNA - A novel biomarker for response to therapy in ovarian carcinoma

被引:101
作者
Kamat, Aparna A.
Bischoff, Farideh Z.
Dang, Dianne
Baldwin, Matthew F.
Han, Liz Y.
Lin, Yvonne G.
Merritt, William M.
Landen, Charles N.
Lu, Chunhua
Gershenson, David M.
Simpson, Joe L.
Sood, Anil K.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77230 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77230 USA
[3] Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA
[4] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
关键词
ovarian cancer; cell-free DNA; therapy; biomarker;
D O I
10.4161/cbt.5.10.3240
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Cell-free DNA (CFDNA) is a reflection of both normal and tumor-derived DNA released into the circulation through cellular necrosis and apoptosis. We sought to determine whether tumor-specific plasma DNA could be used as a biomarker for tumor burden and response to therapy in an orthotopic ovarian cancer model. Methods: Female nude mice injected intraperitoneally with HeyA8 ovarian cancer cells were treated with either docetaxel alone or in combination with anti-angiogenic agents (AEE788 - dual VEGFR and EGFR antagonist or EA5 - monoclonal antibody against ephrin A2). Following DNA extraction from plasma, quantification of tumor-specific DNA was performed by real-time PCR using human specific beta-actin primers. The number of genome equivalents (GE/ml) were determined from a standard curve. Apoptosis was assessed by TUNEL staining of treated tumors. Results: The levels of tumor-specific DNA in plasma increased progressively with increasing tumor burden (R-2 = 0.8, p < 0.01). Additionally, tumor-specific plasma DNA levels varied following treatment with chemotherapy. In mice with established tumors ( 19 days following tumor injection), tumor-specific plasma DNA levels increased by 63% at 24 hours following a single dose of docetaxel (15 mg/kg), and then declined to 20% below baseline at 72 hours and were 83% lower than baseline 10 days following therapy. In addition, docetaxel treatment resulted in a significant increase in the apoptotic index at 24 hours ( p < 0.01). Moreover, in two separate therapy experiments using a combination of cytotoxic chemotherapy with anti-angiogenic agents, tumor-specific plasma DNA levels were significantly higher in mice treated with vehicle compared to the treatment groups. The correlation between tumor weight and tumor-specific DNA in these experiments was 0.71-0.76 ( p < 0.01). Conclusions: Our results indicate that tumor-specific CFDNA levels correlate with increasing tumor burden and decline following therapy. Thus, tumor-specific DNA may be a useful surrogate biomarker of therapeutic response and should be evaluated in future clinical trials.
引用
收藏
页码:1369 / 1374
页数:6
相关论文
共 22 条
[1]   Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients [J].
Anker, P ;
Mulcahy, H ;
Chen, XQ ;
Stroun, M .
CANCER AND METASTASIS REVIEWS, 1999, 18 (01) :65-73
[2]  
[Anonymous], 2000, PRACTICAL GYNECOLOGI
[3]   Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines [J].
Apte, SM ;
Bucana, CD ;
Killion, JJ ;
Gershenson, DM ;
Fidler, IJ .
GYNECOLOGIC ONCOLOGY, 2004, 93 (01) :78-86
[4]   Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease [J].
Boddy, JL ;
Gal, S ;
Malone, PR ;
Harris, AL ;
Wainscoat, JS .
CLINICAL CANCER RESEARCH, 2005, 11 (04) :1394-1399
[5]  
Chen XQ, 1999, CLIN CANCER RES, V5, P2297
[6]   RESPONSE OF HUMAN TUMOR XENOGRAFTS IN ATHYMIC NUDE-MICE TO DOCETAXEL (RP-56976, TAXOTERE(R)) [J].
DYKES, DJ ;
BISSERY, MC ;
HARRISON, SD ;
WAUD, WR .
INVESTIGATIONAL NEW DRUGS, 1995, 13 (01) :1-11
[7]   Circulating tumor-specific DNA: A marker for monitoring efficacy of adjuvant therapy in cancer patients [J].
Fiegl, H ;
Millinger, S ;
Mueller-Holzner, E ;
Marth, C ;
Ensinger, C ;
Berger, A ;
Klocker, H ;
Goebel, G ;
Widschwendter, M .
CANCER RESEARCH, 2005, 65 (04) :1141-1145
[8]   PLASMA DNA AS A MARKER OF CANCEROUS CELL-DEATH - INVESTIGATIONS IN PATIENTS SUFFERING FROM LUNG-CANCER AND IN NUDE-MICE BEARING HUMAN TUMORS [J].
FOURNIE, GJ ;
COURTIN, JP ;
LAVAL, F ;
CHALE, JJ ;
POURRAT, JP ;
PUJAZON, MC ;
LAUQUE, D ;
CARLES, P .
CANCER LETTERS, 1995, 91 (02) :221-227
[9]   Cell-free DNA in human blood plasma: Length measurements in patients with pancreatic cancer and healthy controls [J].
Giacona, MB ;
Ruben, GC ;
Iczkowski, KA ;
Roos, TB ;
Porter, DM ;
Sorenson, GD .
PANCREAS, 1998, 17 (01) :89-97
[10]  
Holdenrieder S, 1999, ANTICANCER RES, V19, P2721